Boosting low white blood cells in blood cancer patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two medicines—thymalfasin and IL-2—to see if they can help raise low white blood cell counts (lymphocytes) in people with blood cancers. If you have low lymphocytes from your cancer or its treatment, this study may offer a way to boost your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer (like leukemia, lymphoma, or multiple myeloma).
- Your lymphocyte count or CD4+ T-cell count must be low (a simple blood test will show this).
- You must be 18 or older and expected to live at least 3 more months.
- Your kidneys and liver must be working fairly well (checked by blood tests).
- You should not have an active autoimmune disease, HIV, or active hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell treatment for adults with a type of blood cancer (B-cell lymphoma) that has come back or not improved after standard treatments. The therapy uses specially engineered immune cells to target and destroy cancer cells.
This trial offers an investigational medicine (Nogapendekin-alfa Inbakicept) that may help raise your lymphocyte (white blood cell) levels, which often drop after cancer treatments. It is for people with solid tumors who have already tried standard therapies and whose immune systems are weak due to low lymphocyte counts.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This study tests a medicine called IL-7 (interleukin-7) that may help raise the number of CD4 cells (a type of immune cell) in people with HIV whose CD4 counts stay low despite effective HIV treatment. The goal is to see if it can improve immune function and potentially reduce infection risk.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.